Nebenwirkungen · Phesgo
Phesgo 600 mg/600 mg solution for injection Phesgo 1 200 mg/600 mg solution for injection · Abschnitt 4.8 · PDF-Seite 20
HOS-147124 · Präparat HOS-099594
In the NEOSPHERE trial, rash occurred in 40.2 % of patients treated with neoadjuvant pertuzumab, trastuzumab and docetaxel compared with 29 % of patients treated with trastuzumab and docetaxel. In the TRYPHAENA trial, rash occurred in 36.8 % of patients treated with neoadjuvant pertuzumab + TCH and 20 % of patients treated with neoadjuvant pertuzumab, trastuzumab and docetaxel following FEC. The incidence of rash was higher in patients who received six cycles of pertuzumab compared with patients who received three cycles of pertuzumab, independent of the chemotherapy given.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T11:50:00Z · SHA-256 a6c98bf6b55eca9607a319c3be5d77798ac324754cdfd92882fd80d342fc312e · Passage 2500756bb86aa92e7c0a52015a571d2fdabe456ee4c55a6a6d12586fa920bd8e · Zeichen 28613–29193 im Abschnitt